
GreenHealth Pharmaceuticals

2022 Annual Report – Sustainability and Financial Performance

Company Overview

GreenHealth Pharmaceuticals is a pioneering leader in sustainable healthcare solutions, dedicated to advancing both health outcomes and environmental goals. Headquartered in Europe, GreenHealth specializes in the development and manufacturing of low-impact pharmaceuticals and is actively engaged in projects that support waste reduction and energy efficiency in line with the EU Taxonomy framework.

In 2022, GreenHealth has focused on expanding its commitment to sustainable practices, with specific attention to aligning our operational footprint with EU environmental goals. This section of the report provides insight into our taxonomy-aligned financial performance as well as our overall annual financials.

1. EU Taxonomy-Aligned Activities and Sustainability Initiatives

GreenHealth's dedication to sustainability is reflected in its compliance with EU Taxonomy regulations, aimed at creating a measurable environmental impact through both eligible and aligned activities. This year, approximately 48% of our turnover qualified as EU Taxonomy-eligible, driven by our extensive line of green pharmaceuticals and waste-minimization efforts.

Aligned with the taxonomy, 40% of our turnover in 2022 directly supports projects that minimize emissions, including the production of low-carbon medications and the installation of energy-efficient manufacturing processes. Our EU Taxonomy-aligned CapEx, which constitutes around 50% of our total CapEx, primarily includes investments in renewable-powered production facilities and advanced waste treatment systems. Additionally, our OpEx includes 35% alignment with taxonomy criteria, with expenditures focused on sustainable sourcing, operational energy savings, and eco-friendly R&D initiatives.

GreenHealth is committed to raising these alignment figures by 10% over the next three years, particularly by scaling up our investments in green technologies and further refining our production processes to adhere to stricter environmental standards.

2. Financial Summary

Alongside our sustainable initiatives, GreenHealth has achieved substantial growth in turnover and expanded our operational capabilities. Below is a summary of our key financial metrics for 2022.

Financial Metric	2022 (€M)	2021 (€M)	Change (%)
Turnover	4,200	3,900	+7.7%
Capital Expenditure (CapEx)	1,200	1,000	+20.0%
Operating Expenditure (OpEx)	950	850	+11.8%
Research & Development (R&D)	600	550	+9.1%
Net Profit	520	500	+4.0%

3. Key Sustainability Achievements in 2022

- **Reduction in Manufacturing Emissions:** Through the installation of a new renewable energy-powered production line, we reduced emissions by 15% at our primary facility in Germany.
- **Sustainable Packaging Initiative:** Introduced 100% recyclable packaging for our primary product lines, reducing plastic waste by an estimated 200 tons annually.
- **Wastewater Treatment Innovations:** Installed advanced wastewater treatment technology across four key manufacturing sites, enhancing water recycling capabilities by 30% and reducing overall water usage by 25%.

4. Outlook for 2023

GreenHealth's sustainability goals for 2023 include the launch of an extensive program to achieve carbon neutrality across all production sites by 2030. This initiative will entail a projected 15% increase in aligned CapEx toward renewable energy installations and further alignment of our OpEx in sustainable sourcing and energy-efficient facility operations. Additionally, we plan to increase R&D investment by 10% to focus on eco-friendly drug development processes.

5. Additional Information and Compliance

This disclosure complies with Sections 3.1–3.3 of the EU Taxonomy reporting framework. For full details on GreenHealth's EU Taxonomy alignment and further information on our sustainable practices, please refer to the complete annual report on our website: <https://www.greenhealthpharma.com/annualreport2022>.

Disclaimer: This report highlights GreenHealth Pharmaceuticals' EU Taxonomy-aligned performance and financials for 2022. Future projections are subject to change based on regulatory developments, economic conditions, and technological advancements.

This format provides a narrative structure for EU Taxonomy data, embedding it in the company's sustainability discussion, while using a financial summary table to present core financial metrics.